Adaptive Trial Design Intelligence

Adaptive Trial Design Intelligence uses advanced AI to design, simulate, and optimize clinical trial protocols in real time across decentralized, adaptive, and externally controlled designs. It integrates real‑world data, trial evidence, and discovery insights to refine eligibility criteria, dosing strategies, and sample sizes as new data emerge. Sponsors gain faster time to statistical readouts, higher trial success probabilities, and more capital‑efficient drug development programs.

The Problem

Adaptive Trial Design Intelligence for faster, lower-risk clinical development

Organizations face these key challenges:

1

Protocol design knowledge is buried in unstructured documents and siloed expert workflows

2

Decentralized trial activities are difficult to map correctly across remote, hybrid, and site-based settings

3

External control arm construction is methodologically complex and labor-intensive

4

Eligibility criteria are hard to analyze systematically for recruitment and outcome impact

5

Recruitment and trial data are fragmented across EDC, CTMS, ePRO, labs, and site systems

6

Static trial simulations become outdated as new evidence emerges

7

Regulatory expectations for adaptive and real-world evidence designs are difficult to operationalize consistently

8

Manufacturing quality and clinical development signals are not integrated for end-to-end decision-making

9

Offline treatment policy optimization is difficult when data is sparse and online experimentation is unsafe

Impact When Solved

Reduce protocol design cycle time by 30-60%Lower protocol amendment frequency through earlier design issue detectionImprove recruitment performance via optimized eligibility criteria and decentralized activity mappingIncrease feasibility of externally controlled and post-approval evidence studiesShorten time to statistical readout through adaptive sample size and dosing optimizationImprove portfolio decision quality with continuously updated trial success predictionsReduce evidence generation cost by using fit-for-purpose real-world data where appropriate

The Shift

Before AI~85% Manual

Human Does

  • Review prior trial evidence, real-world data, and protocol assumptions manually
  • Define eligibility criteria, endpoints, dosing plans, and sample size through expert discussion
  • Monitor recruitment, safety, and data quality through periodic cross-functional review
  • Decide protocol amendments and go/no-go actions based on incomplete interim information

Automation

  • No material AI support in the legacy workflow
  • Limited use of static analytics for reporting and summaries
  • Minimal automated signal detection across trial and external data
With AI~75% Automated

Human Does

  • Approve adaptive design choices, protocol changes, and statistical decision rules
  • Review AI-generated recommendations for eligibility, dosing, sample size, and control strategy
  • Handle safety, compliance, and data-integrity exceptions requiring clinical judgment

AI Handles

  • Continuously analyze trial data, historical evidence, and real-world data to refine design assumptions
  • Simulate adaptive, decentralized, and externally controlled trial scenarios and compare tradeoffs
  • Monitor recruitment, retention, safety, and data quality signals and triage emerging risks
  • Generate protocol optimization recommendations for eligibility criteria, dosing strategy, and sample size

Operating Intelligence

How Adaptive Trial Design Intelligence runs once it is live

AI runs the first three steps autonomously.

Humans own every decision.

The system gets smarter each cycle.

Confidence95%
ArchetypeRecommend & Decide
Shape6-step converge
Human gates1
Autonomy
67%AI controls 4 of 6 steps

Who is in control at each step

Each column marks the operating owner for that step. AI-led actions sit above the divider, human decisions and feedback loops sit below it.

Loop shapeconverge

Step 1

Assemble Context

Step 2

Analyze

Step 3

Recommend

Step 4

Human Decision

Step 5

Execute

Step 6

Feedback

AI lead

Autonomous execution

1AI
2AI
3AI
5AI
gate

Human lead

Approval, override, feedback

4Human
6 Loop
AI-led step
Human-controlled step
Feedback loop
TL;DR

AI handles assembly, analysis, and execution. The human gate sits at the decision point. Every cycle refines future recommendations.

The Loop

6 steps

1 operating angles mapped

Operational Depth

Technologies

Technologies commonly used in Adaptive Trial Design Intelligence implementations:

Key Players

Companies actively working on Adaptive Trial Design Intelligence solutions:

Real-World Use Cases

Agentic AI for clinical trial patient recruitment and data analysis

AI agents read trial rules, search patient records safely, find eligible participants, and combine incoming trial data so teams can make decisions faster.

document understanding plus matching plus continuous monitoringproposed and near-term practical; source presents concrete workflow patterns and quantified recruitment impact but fewer named deployments.
10.0

Real-time agentic clinical trial success prediction and monitoring

An AI team watches clinical trials like expert analysts, predicts whether a study is likely to succeed, and keeps updating that prediction as new evidence appears.

Multi-agent reasoning + monitoring + critique + iterative forecast updatingproposed/early deployed research workflow built on prior published systems and datasets, but described as an emerging agentic layer rather than a broadly commercialized product.
10.0

Offline RL optimization of adaptive treatment strategies with treatment stitching

The system learns better treatment plans from old patient records by combining pieces of real treatment journeys and filling gaps between similar patient states, instead of experimenting on live patients.

sequential decision optimizationproposed research-stage method validated in experiments, not described as deployed in production care workflows.
10.0

Explainable protocol editing support for trial design review

After scoring a new trial protocol, the system points to the specific eligibility rules and design features that pushed the prediction toward failure or success, so clinicians can edit the protocol and try again.

human-in-the-loop decision support with local explanationexperimental decision-support workflow demonstrated in the research pipeline with shap examples on unseen test cases; no evidence of routine operational deployment in the source summaries.
10.0

AI protocol mapping for decentralized trial design and site execution

Use AI to turn FDA decentralized trial guidance into a checklist that maps each study activity to the right setting, such as telehealth, home visit, local provider, or traditional site.

knowledge extraction and decision supportproposed; the source supports the workflow need but does not mention ai deployment.
10.0
+7 more use cases(sign up to see all)

Free access to this report